The burden of prostate cancer is associated with human development index: evidence from 87 countries, 1990–2016
- 18 Downloads
To examine the temporal patterns of the prostate cancer burden and its association with human development.
Subject and methods
The estimates of the incidence and mortality of prostate cancer for 87 countries were obtained from the Global Burden of Disease 2016 study for the period 1990 to 2016. The human development level of a country was measured using its human development index (HDI): a summary indicator of health, education, and income. The association between the burden of prostate cancer and the human development index (HDI) was measured using pairwise correlation and bivariate regression. Mortality-to-incidence ratio (MIR) was employed as a proxy for the survival rate of prostate cancer.
Globally, 1.4 million new cases of prostate cancer arose in 2016 claiming 380,916 lives which more than doubled from 579,457 incident cases and 191,687 deaths in 1990. In 2016, the age-standardised incidence rate (ASIR) was the highest in very high–HDI countries led by Australia with ASIR of 174.1/100,000 and showed a strong positive association with HDI (r = 0.66); the age-standardised mortality rate (ASMR), however, was higher in low-HDI countries led by Zimbabwe with ASMR of 78.2/100,000 in 2016. Global MIR decreased from 0.33 in 1990 to 0.26 in 2016. Mortality-to-incidence ratio (MIR) exhibited a negative gradient (r = − 0.91) with human development index with tenfold variation globally with seven countries recording MIR in excess of 1 with the USA recording the minimum MIR of 0.10.
The high mortality and lower survival rates in less-developed countries demand all-inclusive solutions ranging from cost-effective early screening and detection to cost-effective cancer treatment. In tackling the rising burden of prostate cancer predictive, preventive and personalised medicine (PPPM) can play a useful role through prevention strategies, predicting PCa more precisely and accurately using a multiomic approach and risk-stratifying patients to provide personalised medicine.
KeywordsProstate cancer Incidence Mortality Mortality-to-incidence ratio Human development index Predictive preventive personalised medicine Precision medicine
We thank the Institute of Health Metrics and Evaluation (IHME) for making Global Burden of Disease (GBD) data pertaining to prostate cancer available in the public domain.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
The research is conducted using data available in the public domain and does not include any human participants and/or animals.
- 1.Global Burden of Disease Cancer Collaborators. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016 a systematic analysis for the Global Burden of Disease Study. JAMA Oncol. 2018;4:1553. https://doi.org/10.1001/jamaoncol.2018.2706.CrossRefGoogle Scholar
- 8.Sunkara V, Hebert JR. The colorectal cancer mortality-to-incidence ratio as an indicator of global cancer screening and care. Cancer 2015. 2015;121(10):1563–9.Google Scholar
- 10.Sharma R. Breast cancer incidence, mortality and mortality-to-incidence ratio (MIR) are associated with human development, 1990–2016: evidence from Global Burden of Disease Study 2016. Breast Cancer. 2019:1–18. https://doi.org/10.1007/s12282-018-00941-4.
- 11.Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2016 (GBD 2016) results. Seattle, United States: Institute for Health Metrics and Evaluation (IHME), 2017. Available from http://ghdx.healthdata.org/gbd-results-tool (Accessed: August 14–16, 2018).
- 12.GBD 2016 Disease and Injury, Incidence and Prevalence collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390:1211–59.CrossRefGoogle Scholar
- 13.Foreman KJ, Lozano R, Lopez AD, Murray CJ. Modeling causes of death: an integrated approach using CODEm. Popul Health Metrics. 2012;10(1).Google Scholar
- 14.Human Development Database: http://hdr.undp.org/en/data# (Accessed: 30.6.2018 and 1.7.2018).
- 22.Grossman DC, Curry SJ, Owens DK, Bibbins-Domingo K, Caughey AB, Davidson KW, et al. Screening for prostate cancer: US Preventive Services Task Force recommendation statement. Jama. 2018;19:1901–13.Google Scholar
- 29.Horgan RP, Kenny LC. ‘Omic’ technologies: genomics, transcriptomics, proteomics and metabolomics. Obstet Gynaecol. 2011;13:189–95.Google Scholar
- 34.Huang YQ, Sun T, Zhong WD, Wu CL. Clinical performance of serum [-2] proPSA derivatives, % p2PSA and PHI, in the detection and management of prostate cancer. Am J Clin Exp Urol. 2014;2:343.Google Scholar